journal article·2025-10Open access

Astrocyte Interactions With Ti 3 C 2 T x MXene Flakes: Insights Into Viability, Morphology, and Functionality

Dimitris Boufidis, Elizabeth N. Krizman, Cybelle M. Smith, Yihan Xie, Raghav Garg, John C. O'Donnell, Flavia Vitale, D. Kacy Cullen

Advanced Materials Interfaces· Volume 12· Issue 20

Abstract

Abstract Astrocytes, the most abundant cell type in the brain, are increasingly recognized as active regulators of neuronal function and potential therapeutic targets. Two‐dimensional MXenes, such as titanium carbide (Ti 3 C 2 T x ), hold promise for neural interfaces and bioelectronic applications owing to their favorable electrochemical properties, but their compatibility with glial cells has yet to be investigated. Here, the first systematic evaluation of astrocyte–MXene interactions is reported by exposing cortical rat astrocytes to varying concentrations of Ti 3 C 2 T x in aqueous dispersions. Phase contrast and scanning electron microscopy showed individual flakes and larger aggregates on astrocyte membranes with no detectable damage. Cytotoxicity assays demonstrated robust astrocyte viability, morphological analysis indicated no significant changes in cell structure, and calcium imaging revealed no changes in spontaneous Ca 2 ⁺ activity between control and Ti 3 C 2 T x ‐treated cultures. These findings establish a foundation for the integration of Ti 3 C 2 T x into next‐generation neural interfaces while underscoring the need for further exploration of MXene‐based tools for astrocyte‐targeted neuromodulation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: MXene and MAX Phase Materials · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering University of Pennsylvania Philadelphia Pennsylvania 19104 USA

Center for Neurotrauma, Neurodegeneration & Restoration Corporal Michael J. Crescenz VA Medical Center Philadelphia Pennsylvania 19104 USA

Center for Neuroengineering and Therapeutics University of Pennsylvania Philadelphia Pennsylvania 19104 USA

Department of Neurosurgery University of Pennsylvania Philadelphia Pennsylvania 19104 USA

Department of Neurology University of Pennsylvania Philadelphia Pennsylvania 19104 USA

Funding

National Science Foundation · Alexander S. Onassis Public Benefit Foundation · National Institute of Neurological Disorders and Stroke

References (59)

Show source-provided references
1. 10.1038/457675a10.1038/457675a ↗
2. 10.1126/science.aat047310.1126/science.aat0473 ↗
3. 10.1016/j.expneurol.2015.03.02010.1016/j.expneurol.2015.03.020 ↗
4. 10.1152/physrev.00042.201610.1152/physrev.00042.2016 ↗
5. 10.1016/j.tins.2009.05.00110.1016/j.tins.2009.05.001 ↗
6. 10.1038/s41573-022-00390-x10.1038/s41573-022-00390-x ↗
7. 10.1097/01.WCB.0000044631.80210.3C10.1097/01.WCB.0000044631.80210.3C ↗
8. 10.1016/j.neuron.2008.10.01310.1016/j.neuron.2008.10.013 ↗
9. 10.1038/nn.418410.1038/nn.4184 ↗
10. 10.1038/s41467-021-23843-010.1038/s41467-021-23843-0 ↗
11. 10.1016/j.tins.2017.04.00110.1016/j.tins.2017.04.001 ↗
12. 10.1101/cshperspect.a03518810.1101/cshperspect.a035188 ↗
13. 10.1038/s41593-018-0325-810.1038/s41593-018-0325-8 ↗
14. 10.1038/s41562-024-01941-510.1038/s41562-024-01941-5 ↗
15. 10.1038/s41586-023-06094-510.1038/s41586-023-06094-5 ↗
16. 10.1038/s41586-023-06443-410.1038/s41586-023-06443-4 ↗
17. 10.1073/pnas.212080811910.1073/pnas.2120808119 ↗
18. 10.1038/s41467-025-57016-010.1038/s41467-025-57016-0 ↗
19. Carnicer‐Lombarte A. · Systematic Review · 2021 · 9
20. 10.1038/s41551-017-0154-110.1038/s41551-017-0154-1 ↗
21. 10.1038/s41565-024-01711-410.1038/s41565-024-01711-4 ↗
22. 10.1038/s44222-023-00022-y10.1038/s44222-023-00022-y ↗
23. 10.1557/s43577-023-00480-010.1557/s43577-023-00480-0 ↗
24. 10.1021/acsnano.8b0601410.1021/acsnano.8b06014 ↗
25. 10.1021/acsnano.1c0443110.1021/acsnano.1c04431 ↗
26. 10.1186/s12951-022-01590-810.1186/s12951-022-01590-8 ↗
27. 10.1002/adhm.20200126810.1002/adhm.202001268 ↗
28. 10.1021/acs.chemrestox.0c0023210.1021/acs.chemrestox.0c00232 ↗
29. 10.1002/adhm.20230233010.1002/adhm.202302330 ↗
30. 10.1002/smtd.20230019710.1002/smtd.202300197 ↗
31. D.Boufidis presented at the 2025 Annual Meeting (AAAS) Boston MA USA 2025.
32. 10.1002/smtd.20220131810.1002/smtd.202201318 ↗
33. 10.1021/acs.chemmater.0c0035910.1021/acs.chemmater.0c00359 ↗
34. 10.1021/acs.est.9b0537210.1021/acs.est.9b05372 ↗
35. 10.20964/2018.11.5610.20964/2018.11.56 ↗
36. "NEUROBASAL™ Medium (1X) liquid ‐ US." Thermo Fisher Scientific. https://www.thermofisher.com/us/en/home/technical‐resources/media‐formulation.251.html(accessed: March 2025).
37. 10.1016/j.envres.2021.11159210.1016/j.envres.2021.111592 ↗
38. 10.1016/j.actbio.2020.12.03510.1016/j.actbio.2020.12.035 ↗
39. 10.3390/neuroglia301000310.3390/neuroglia3010003 ↗
40. 10.3389/fncel.2017.0023510.3389/fncel.2017.00235 ↗
41. 10.1016/j.neuron.2017.12.00210.1016/j.neuron.2017.12.002 ↗
42. 10.1111/jnc.1623710.1111/jnc.16237 ↗
43. 10.1186/s40659-024-00532-y10.1186/s40659-024-00532-y ↗
44. 10.1021/acsbiomaterials.4c0022910.1021/acsbiomaterials.4c00229 ↗
45. 10.1021/acs.nanolett.8b0248710.1021/acs.nanolett.8b02487 ↗
46. 10.1186/s12974-023-02752-710.1186/s12974-023-02752-7 ↗
47. 10.3389/fnsys.2018.0001210.3389/fnsys.2018.00012 ↗
48. 10.3389/fnsyn.2023.113857710.3389/fnsyn.2023.1138577 ↗
49. 10.1002/smll.20190014710.1002/smll.201900147 ↗
50. 10.1007/s00204-021-03032-010.1007/s00204-021-03032-0 ↗
51. 10.1038/nn.400110.1038/nn.4001 ↗
52. 10.1016/j.biopha.2022.11349610.1016/j.biopha.2022.113496 ↗
53. 10.1083/jcb.85.3.89010.1083/jcb.85.3.890 ↗
54. 10.1002/jnr.2143410.1002/jnr.21434 ↗
55. 10.1002/term.216810.1002/term.2168 ↗
56. Katiyar K. S. · J. Vis. Exp. · 2018 · 131
57. 10.1021/acs.chemmater.7b0284710.1021/acs.chemmater.7b02847 ↗
58. 10.1046/j.1365-2818.1997.1940755.x10.1046/j.1365-2818.1997.1940755.x ↗
59. 10.1007/978-3-540-85920-8_1210.1007/978-3-540-85920-8_12 ↗